Hims & Hers partners with Novo Nordisk, shifts US weight loss strategy to FDA-approved GLP-1s

Hims & Hers Health, Inc.

Collaboration with Novo Nordisk to offer Ozempic and Wegovy on platform starting March 2026.
Will no longer advertise compounded GLP-1s; limited compounding only for clinical necessity.
Novo Nordisk dismisses its lawsuit against Hims & Hers without prejudice.
Existing patients can transition to FDA-approved GLP-1s when clinically appropriate.
CEO Dudum: partnership enables scaled distribution of innovations for affordable access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.